Se Ik Kim

Dr. Se Ik Kim

Seoul National University College of Medicine: Seoul, KR
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Oncogene
Verified
Journal Article
Closed access
YHYoungjin Han
Youngjin Han
BKBoyun Kim
Boyun Kim
UCUntack Cho
Untack Cho
IPIn Sil Park
In Sil Park
SKSe Ik Kim
Se Ik Kim
Yong Sang SongYong Sang Song
Yong Sang Song

17 September 2018 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
SKSoochi Kim
Soochi Kim
YHYoungjin Han
Youngjin Han
SKSe Ik Kim
Se Ik Kim
HKHee-Seung Kim
Hee-Seung Kim
SKSeong Jin Kim
Seong Jin Kim
Yong Sang SongYong Sang Song
Yong Sang Song
Development of novel strategies to overcome chemoresistance is central goal in ovarian cancer research. Natural history of the cancer development and progression is being reconstructed by genomic datasets to understand the evolutionary pattern and direction. Recent studies suggest that intra-tumor heterogeneity (ITH) is the main cause of treatment failure by chemoresistance in many types of cancers including ovarian cancer. ITH increases the fitness of tumor to adapt to incompatible microenvironment. Understanding ITH in relation to the evolutionary pattern may result in the development of the innovative approach based on individual variability in the genetic, environment, and life style. Thus, we can reach the new big stage conquering the cancer. In this review, we will discuss the recent advances in understanding ovarian cancer biology through the use of next generation sequencing (NGS) and highlight areas of recent progress to improve precision medicine in ovarian cancer.

1 April 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
SKSe Ik Kim
Se Ik Kim
JCJae Hyun Cho
Jae Hyun Cho
ASAeran Seol
Aeran Seol
YKYoung Im Kim
Young Im Kim
MLMaria Lee
Maria Lee
Yong Sang SongYong Sang Song
Yong Sang Song

1 September 2015 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
SKSe Ik Kim
Se Ik Kim
MLMyong Cheol Lim
Myong Cheol Lim
JLJeong Seon Lee
Jeong Seon Lee
YLYumi Lee
Yumi Lee
KPKiByung Park
KiByung Park
SPSang-Yoon Park
Sang-Yoon Park

1 October 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
SKSe Ik Kim
Se Ik Kim
MLMaria Lee
Maria Lee
SLSungyoung Lee
Sungyoung Lee
DSDong Hoon Suh
Dong Hoon Suh
HKHee Seung Kim
Hee Seung Kim
YKYong Beom Kim
Yong Beom Kim

7 May 2019 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
SKSe Ik Kim
Se Ik Kim
MLMaria Lee
Maria Lee
HKHee Seung Kim
Hee Seung Kim
HCHyun Hoon Chung
Hyun Hoon Chung
HKHak Jae Kim
Hak Jae Kim
Yong Sang SongYong Sang Song
Yong Sang Song
To evaluate impact of germline BRCA mutational status on prognosis in patients with advanced ovarian cancer. A total of 128 patients diagnosed with FIGO stage III-IV high-grade serous ovarian cancer (HGSOC) between 2008 and 2017 and underwent BRCA1/2 gene testing at the time of or within two years from cancer diagnosis were included in this study. We compared patients’ clinicopathological characteristics and survival outcomes after primary treatment according to germline BRCA mutational status. Treatment-related factors that might affect patients’ survival outcome were also investigated. Germline BRCA1/2 mutations were observed in 51 women (39.8%). There were no differences in age and serum CA-125 levels at the time of HGSOC diagnosis, use of neoadjuvant chemotherapy (NAC), extent of debulking surgery, and overall survival (OS) between the BRCA mutation and wild-type BRCA groups. In contrast, the BRCA mutation group displayed longer progression-free survival (PFS) (median, 22.9 vs. 16.9 months, P = 0.001). Multivariate analyses identified germline BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted HR, 0.502; 95% CI, 0.318–0.795; P = 0.003). In the wild-type BRCA group, patients who received NAC as the primary treatment had shorter PFS compared to those who received primary debulking surgery (PDS) (median, 14.2 vs. 16.9 months, P = 0.003). However, in the BRCA mutation group, PFS did not differ between the NAC and PDS groups (P = 0.082). In advanced-stage HGSOC, patients with germline BRCA1/2 mutations have better prognosis with longer PFS than those lacking BRCA mutations. Prognosis after NAC was different according to the BRCA mutational status.